<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03871088</url>
  </required_header>
  <id_info>
    <org_study_id>NHRI-EX105-10528NI</org_study_id>
    <nct_id>NCT03871088</nct_id>
  </id_info>
  <brief_title>N-3 Fatty Acids as the First-line Antidepressant Therapy: From Biomarkers to Clinical Subtypes</brief_title>
  <official_title>N-3 Fatty Acids as the First-line Antidepressant Therapy: From Biomarkers to Clinical Subtypes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Science Council, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Science Council, Taiwan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigate the clinical subtypes and the biological markers to personalize the use n-3 PUFAs
      (EPA, DHA, and EPA/DHA) in MDD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this proposal, the investigators aim to explore the clinical subtypes and biological
      markers to personalize the use n-3 PUFAs (EPA, DHA, and EPA/DHA) in MDD. By stratifying the
      subjects with (versus without) remission and treatment response, the biological markers are
      expected to have important prediction effects in future clinical practice.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2015</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Rating Scale for Depression (HAMD) Changes</measure>
    <time_frame>From Week 0 to Week 12</time_frame>
    <description>The Changes of scores in Hamilton Rating Scale for Depression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>at Week 12</time_frame>
    <description>50% decreases in the Hamilton Rating Scale for Depression from W0 to W12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission rate</measure>
    <time_frame>at Week 12</time_frame>
    <description>Less than 8 points in the Hamilton Rating Scale for Depression at W12</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">400</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Eicosapentaenoic acid (EPA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eicosapentaenoic acid (EPA) is an omega-3 fatty acid. In physiological literature, it is given the name 20:5(n-3).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Docosahexaenoic acid (DHA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docosahexaenoic acid (DHA) is an omega-3 fatty acid. In physiological literature, it is given the name 22:6(n-3).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EPA/DHA combination</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EPA/DHA means the combination of omega-3 fatty acids Eicosapentaenoic and Docosahexaenoic acids.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Omega-3 fatty acids</intervention_name>
    <description>12-week double-blind, randomized controlled trial</description>
    <arm_group_label>Docosahexaenoic acid (DHA)</arm_group_label>
    <arm_group_label>EPA/DHA combination</arm_group_label>
    <arm_group_label>Eicosapentaenoic acid (EPA)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  the diagnostic criteria of DSM-IV for MDD

          -  18 to 65 years old

          -  pre-study ratings of 18 or greater on the 21-item Hamilton Rating Scale for Depression
             (HAMD)

          -  physically healthy under comprehensive evaluations in medical history, physical
             examination, and laboratory parameters tests

          -  have not received any psychiatric treatment in 2 weeks

          -  competent to receive a full explanation of this study and give written informed
             consent.

        Exclusion Criteria:

          -  a recent or past history of other DSM-IV AxisI diagnoses besides unipolar major
             depression, including psychotic disorders, organic mental disorders, impulse control
             disorders, substance use disorder or substance abuse (last 6 months prior to the
             study), and bipolar disorders

          -  AxisII diagnoses, including borderline and antisocial personality disorder

          -  a notable medical comorbidity

          -  acutely suicidal ideation and attempt were noted that close monitoring such as
             hospitalization is necessary

          -  regular consumption of omega-3 PUFAs supplements or a habit of eating Ô¨Åsh equal or
             more than 4 times per week
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>404</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 7, 2019</study_first_submitted>
  <study_first_submitted_qc>March 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2019</study_first_posted>
  <last_update_submitted>March 8, 2019</last_update_submitted>
  <last_update_submitted_qc>March 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Science Council, Taiwan</investigator_affiliation>
    <investigator_full_name>Kuan-Pin</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Depression, omega-3 fatty acids, nutritional intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

